ArticleGlobalization and health2025
The successful scaling-up of antiretroviral therapy globally has many lessons for advancing universal health coverage: progress at risk.
Article in Globalization and health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Article
- Pretreatment HIV-1 drug resistance and molecular subtype characteristics among newly diagnosed individuals in Guangxi, China.AIDS research and therapy · 2026Article
- Exploring the factors influencing loss to follow up among patients living with HIV& AIDS on antiretroviral therapy in the Northern Region of Ghana: a qualitative study.BMC public health · 2026Article
- Pharmaceutical access in medical security systems and health policy mobilization: cross-national evidence on TRIPS compulsory licensing from 2001 to 2024.Frontiers in public health · 2026Article
- Urate dysregulation (hyperuricemia and gout) among people living with HIV: A protocol for a systematic review and meta-analysis.PloS one · 2026Article
- Adjunctive albuvirtide is associated with improved immune recovery in treatment-naive patients with advanced HIV disease receiving bictegravir/emtricitabine/tenofovir alafenamide: a retrospective propensity score-matched cohort study.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe expansion of antiretroviral therapy (ART) over the past twenty years is one of the most significant achievements in public health. It has transformed HIV from a life-threatening to a chronically manageable condition. This study aims to identify the successes and challenges in scaling up ART over the past two decades and derive key lessons to inform the universal health coverage (UHC) agenda.
methodsThe World Health Organization’s (WHO) Global Health Observatory database was used to extract data on ART coverage. We analysed ART coverage data for all countries in the six WHO Regions (Africa, the Americas, Eastern Mediterranean, Europe, Southeast Asia, and Western Pacific) of the world from 2000 to 2023. We also examined the association between ART coverage and UHC for reproductive, maternal, neonatal, and child health services in the African region. A trend analysis of HIV funding from 2000 to 2023 was also conducted using the data from the National AIDS Spending Assessment. A literature review was conducted to identify the factors that facilitate or hinder the expansion of ART, along with key insights for the UHC agenda.
resultsART coverage has increased significantly across all regions, from 2% in 2000 to 77% in 2023. Africa experienced the most remarkable growth, rising from 0% in 2000 to 82% in 2023. ART coverage positively correlates with improvements in reproductive, maternal, neonatal, and child health services. However, there are notable disparities in ART coverage across regions, with Africa leading but with significant variation between countries, while the Eastern Mediterranean Region lags. A slowdown in ART coverage growth has been observed since 2020, reflecting challenges in sustaining progress as countries near universal coverage and struggle to reach marginalized or criminalized populations with limited access to healthcare. Additionally, global HIV funding, which peaked in 2017, has plateaued and declined by 2023. The successful scaling up of ART relies on strong political leadership, health system strengthening, community engagement, multi-sectoral actions, and global health initiatives. Key lessons for UHC include maintaining political commitment, strengthening health systems, reducing financial barriers, engaging communities and other sectors, and ensuring long-term financial sustainability.
conclusionsThe global scale-up of ART has been a major public health success, though disparities remain, and the rate of growth of ART coverage has slowed since 2020 due to financial instability, shifting global health priorities, and the COVID-19 pandemic. These gains are thus now at risk. Moving forward, strong political leadership, resilient health systems, community engagement, multi-sectoral collaboration, and sustainable financing are essential for maintaining and expanding ART coverage. These lessons are critical for advancing the UHC agenda.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.